Health Technology · Pharmaceuticals: Major · NSE: BLISSGVS · data 2026-10-09
Bliss GVS Pharma Limited
Health check: Strong (6.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹655.95
Market cap
₹7,138 cr
P/E
52
P/B
—
ROE
11.5%
ROCE
10.9%
Debt / equity
0.02
Dividend yield
0.22%
1-year return
328.7%
52-week high
₹739.9
52-week low
₹118
Operating margin
15.1%
Growth
| Revenue (last 12 months) | ₹1,005 cr |
| Net profit (last 12 months) | ₹136 cr |
| Sales growth, 3 years (yearly) | 7.2% |
| Profit growth, 3 years (yearly) | 22.1% |
Chart patterns
- Ascending triangle — forming (key level ₹739.9)
Similar companies
Morepen Laboratories Limited (MOREPENLAB) · Symbiotec Pharmalab Limited (SYMBIOTEC) · Supriya Lifescience Limited (SUPRIYA) · Sanofi India Limited (SANOFI) · Innova Captab Limited (INNOVACAP)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BLISSGVS in NSE Scanner →